Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant

Table 7 Distribution of patients in groups 1 and 2 depending on the combination of the lack of cytoplasmic programmed cell death protein 1 ligand 1 tumor cells and cytoplasmic programmed cell death protein 1 ligand 1 immune cell scores

The combination of the lack of cPDCD1 LG1 in TCs and PDCD1 LG1 IC scores	1 group (luminal A BC)	2 group (BC with Ki67 ≥ 40%)	P value (χ2 test)
BC with the lack of cPDCD1 LG1 in < 20% of the TCs and PDCD1 LG1 IC scores < 10%	28 (87.5)	4 (12.5)	< 0.0000
BC with the lack of cPDCD1 LG1 in ≥ 20% of the TCs and PDCD1 LG1 IC scores < 10%	14 (58.3)	10 (41.7)
BC with the lack of cPDCD1 LG1 in < 20% of the TCs and PDCD1 LG1 IC scores ≥ 10%	10 (55.6)	8 (44.4)
BC with the lack of cPDCD1 LG1 in ≥ 20% of the TCs and PDCD1 LG1 IC scores ≥ 10%	4 (15.4)	22 (84.6)

BC: Breast cancer; cPDCD1 LG1: Cytoplasmic programmed cell death protein 1 ligand 1; ICs: Immune cells; TCs: Tumor cells.